All News
JAK or TNF Inhibitor as First Drug for Rheumatoid Arthritis?
d
Medpage Today
A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic drugs had failed, a pragmatic head-to-head trial found.
Read Article
2023 EULAR classification criteria for hand osteoarthritis
A EULAR consensus group has established classification criteria for overall hand osteoarthritis (OA) and its subtypes (interphalangeal OA and thumb base OA).
The criteria require two mandatory criteria to be met:
ACR Calls on CMS for Enhanced Transparency & Reporting
The American College of Rheumatology has submitted its response to the Centers for Medicare & Medicaid Services (CMS) request for information and feedback from stakeholders on how best to enhance Medicare Advantage data capabilities and increase public transparency.
Read Article
Role of Diet in Gout Risk
Diet has long been influential in gout care and risks. A large cohort study has shown that plant-based diets may reduce the risk of developing gout.
This prospective study assessed the risk of developing incident gout based on consumption of healthy and unhealthy plant-based diets.
Systemic sclerosis sine scleroderma in children is more aggressive than in adults. 18 juvenile vs 38 adults - ssJSSc more female (39% vs 89%), more digital pitting scars/ulcers (35 vs 10.5%), Pulm (50 vs 24) & CV (50 vs 3%); w/ more deaths https://t.co/l4f5bH1IX1 https://t.co/viQcD3tN9V
Dr. John Cush RheumNow ( View Tweet)
Australian study of informal caregivers (not iworking) of arthritis pts shows excess cose of $388 million (in 2015), expected to increase to $576.9 million by 2030. Informal caregivers less likely to work, due to the demands & duties of their caregiving https://t.co/Gw1eIBN6WW https://t.co/h1TY0BtaSE
Dr. John Cush RheumNow ( View Tweet)
Disjointed incomplete arthritis care! 82 arthritis pts w/ new complaints surveyed; 29% went to the ED (1/3 repeat visit) for arthritis flare. Only 26% referred to a rheumatologist of which 38% were unable to do so in the time frame suggested. https://t.co/f3RbhdKL8u https://t.co/C1iRsQoiAJ
Dr. John Cush RheumNow ( View Tweet)
Canadian study of 44,438 older adults (age 76) w/ gout found only 52% reached serum uric acid (SUA) target w/in 12-mos, improving from 45% (2010) to 61% (2019). ULT adherence was 55%, also improved annually. Only 3.5% Rx by Rheumatologist! https://t.co/vAc8myxiRm https://t.co/gcMz379iPH
Dr. John Cush RheumNow ( View Tweet)
Review of 31 FDA Rheum drug approvals betw 1995-2021 showed patient-reported outcomes seldom reported or published. Despite meeting MCID (57%) & significance (85%), 1/3 PROs not reported & 10% remained unpublished (4yrs later) https://t.co/pvGhTxlP03 https://t.co/t3VEHw7FJv
Dr. John Cush RheumNow ( View Tweet)
FDA has approved upadacitinib (Rinvoq), for use in pediatric patients (age >2 years) w/ active polyarticular juvenile idiopathic arthritis (pJIA) & psoriatic arthritis (PsA), after inadequate resp/intolerance to TNFi. Also available as oral solution. https://t.co/lGvIHb8wfZ https://t.co/8BiTnTNJzO
Dr. John Cush RheumNow ( View Tweet)
Review of the Scleroderma spectrum disorders (full-read) https://t.co/xaIxf8q0Tj https://t.co/kxFiQTqKqV
Dr. John Cush RheumNow ( View Tweet)
Boxed Warnings in Derm:
- Topical Calcineurin inhib (atopic dermatitis): rare risk of cancer
- IL-17 Inhibitors (PSO, PsA): exacerbation of IBD (38 RCTs: only 12/16,690 new IBD case
- Psoriasis and suicidality: suicide risk same w/ or without treatments https://t.co/HsjO78NtjP https://t.co/v9Pys8RwcH
Dr. John Cush RheumNow ( View Tweet)
Cohort study of 25 315 women followed 25 years shows adherence to the Mediterranean diet associated with a 23% reduced all-cause mortality - explained by lipids, inflammation markers and BMI; more than cholesterol or glycemic measures https://t.co/kgj18lG12G https://t.co/NN2FlPSngW
Dr. John Cush RheumNow ( View Tweet)
TriNetX US claims study of 7580 RA pts Rx w/ tofacitinib or adalimumab found Tofa signif. more likely to cause dyslipidemia (HR 1.250), but no difference betw TOFA & ADA in MACE (HR 0.995; 0.76–1.3) or all-cause mortality (HR 1.4; 0.89–2.2) https://t.co/83CGng2R9e https://t.co/QfD4ePuTER
Dr. John Cush RheumNow ( View Tweet)
ACR’s Run at Goliath (PCPs) (5.31.2024)
The ACR (and Cush) address their new website designed to educate PCPs and APPs - what do you think?
https://t.co/DQOkhowU0b https://t.co/MK9aVe7Yaf
Dr. John Cush RheumNow ( View Tweet)
We are covering #EULAR24! We'll be sharing recaps, videos, and more.
https://t.co/7ehREq5gnl https://t.co/ao2LzcFxrt
Links:
Dr. John Cush RheumNow ( View Tweet)
Full read review on Psoriasis Flares; risks:
- mechanical stress
- infections
-dysbiosis
-drugs (Lithium, B-blockers, HCQ, tetracyclines, ACEi, IFN)
- environment(smoking, obesity)
-lifestyle
- stress
- hormonal/metabolic https://t.co/dpnVS05Pm7 https://t.co/l3rdxaBSgV
Links:
Dr. John Cush RheumNow ( View Tweet)
NEJM Images - Polyarteritis Nodosa. 62 yoM with myalgias, wt loss, numbness, negative ANCA & HBV. Abdominal angiography shows multiple aneurysms. https://t.co/Axaobo01wD https://t.co/y2XYg6kVjB
Links:
Dr. John Cush RheumNow ( View Tweet)
Forbes on the future of CAR-T cell therapy - A Gamechanger For Autoimmune Diseases. Innovation, costs, more trials and regulatory differences for autoimmune (vs cancer) patietns? https://t.co/6Siv0Y1GDB https://t.co/Mmbh4ER7vf https://t.co/j8bgn8DkLw
Dr. John Cush RheumNow ( View Tweet)
Colchicine prophylaxis w/ allopurinol (“start-low go-slow” 100mg escalation strategy), is best used in pts w/ gout flare in month prior to allopurinol. Longer prophylaxis may be required w/ ongoing flares in 1st 6mos of allopurinol if T2T not achieved https://t.co/yupiq26BJA https://t.co/KDF394SC30
Dr. John Cush RheumNow ( View Tweet)